Based on these findings, TGF-β signaling appears to be a potential target for HCC treatment, and the direct inhibition of ALK5 might be an attractive approach to prevent detrimental tumor progression due to TGF-β signaling. This evidence concerns the gene TGFBR1 and hepatocellular carcinoma.